La cadena de opciones muestra datos clave de las opciones de acciones de DBV Technologies a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para DBV Technologies..

DBV Technologies (NASDAQ:DBVT) Bolsa, Cadena de Opciones

DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

On Tuesday, DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) announced progress in its regulatory efforts for the Viaskin Peanut patch, aimed at treating peanut allergies in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41467627/dbv-announces-positive-regulatory-updates-for-the-viaskin-peanut-patch-in-the-united-states-and-eu" rel="noreferrer noopener">toddlers and children</a>.
The company has aligned with the FDA under the Accelerated Approval Program for toddlers aged 1–3.
DBV has agreed to the FDA&#8217;s guidance on key study components required for approval, including the COMFORT Toddlers safety study, which must be completed before the US marketing application submission, and a confirmatory study to demonstrate the patch&#8217;s effectiveness.
DBV plans to begin enrolling subjects in the COMFORT Toddlers study in the second quarter of 2025, with <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33487292/dbv-technologies-advances-peanut-allergy-program-with-fda-support-on-pediatric-studies" rel="noreferrer noopener">around 300–350 toddlers</a>.
DBV has also made headway on the Viaskin Peanut patch for older children. In September 2024, the company completed patient screening for the Phase 3 VITESSE trial, enrolling 654 children aged 4–7 years. Topline data are expected in the fourth quarter of 2025.
Discussions between DBV and the FDA have also addressed the patch&#8217;s adhesion issues. The company proposed a labeling solution that links adhesion data to the patch&#8217;s efficacy and safety.
DBV also received scientific advice from the European Medicines Agency for a broader age range of 1–7 years in Europe.
In Europe, DBV has received scientific advice confirming that the EPITOPE study in 1–3-year-olds and positive results from the VITESSE study could support the European marketing application for the 1–7-year-old age group.
The company is planning a new safety study for toddlers with the modified patch to meet European requirements.
Despite its clinical progress, DBV&#8217;s financial situation raises concerns. The company reported cash and cash equivalents of $46.4 million as of September 30, 2024, and anticipates that this will fund operations only through the first quarter of 2025.
With ongoing operating losses, DBV has expressed uncertainty about its ability to continue operations without securing additional funding. The company is actively seeking new capital to support its research and potential product launch.
Price Action: DBVT stock is up 44.3% at $1.02 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41486950/boeing-q3-earnings-revenue-and-profit-decline-cultural-challenges-ceo-ortberg-vows-transformation" target="_blank" rel="noreferrer noopener">Boeing Q3 Earnings: Revenue And Profit Decline, Cultural Challenges, CEO Ortberg Vows Transformation</a>.</li>
</ul>

News

Health Care

Movers

General

DBVT

Penny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval Pathway

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 92.5% to $0.3 during Wednesday's regular session. The company's market cap stands at $9.6 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock rose 63.89% to $2.75. The market value of their outstanding shares is at $11.9 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 59.31% to $2.56. The company's market cap stands at $437.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 42.54% to $1.0. The company's market cap stands at $95.9 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 36.35% to $1.65. The company's market cap stands at $343.5 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 22.47% to $4.12. The market value of their outstanding shares is at $32.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares declined by 66.1% to $4.93 during Wednesday's regular session. The market value of their outstanding shares is at $132.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 27.74% to $0.33. The market value of their outstanding shares is at $4.4 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 26.44% to $0.4. The company's market cap stands at $5.4 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 25.26% to $0.72. The market value of their outstanding shares is at $2.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 25.18% to $1.07. The company's market cap stands at $2.1 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 23.73% to $1.8. The market value of their outstanding shares is at $3.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANRO

BIVI

CNSP

CYCC

ENSC

ALPS ETF Trusthen & Steers Global Realty Majors ETF

NUWE

SGMO

SLXN

TVGN

VRAX

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

DBV Technologies shares are trading higher after the company announced regulatory updates for the Viaskin Peanut patch in the United States and Europe.

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock moved upwards by 143.7% to $0.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $12.2 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock increased by 62.87% to $1.14. The market value of their outstanding shares is at $109.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 46.15% to $2.09. The company's market cap stands at $4.1 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares moved upwards by 34.59% to $0.38. The market value of their outstanding shares is at $14.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) shares moved upwards by 25.49% to $3.2. The market value of their outstanding shares is at $61.0 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares increased by 19.34% to $4.01. The company's market cap stands at $32.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) stock decreased by 62.3% to $5.48 during Wednesday's pre-market session. The company's market cap stands at $147.7 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 18.58% to $0.44. The market value of their outstanding shares is at $6.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock declined by 14.49% to $3.07. The company's market cap stands at $7.9 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) stock decreased by 14.46% to $2.13. The company's market cap stands at $52.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock fell 12.7% to $0.31. The market value of their outstanding shares is at $4.1 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock decreased by 11.51% to $4.0. The company's market cap stands at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

CELZ

GNPX

MBIO

TELA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 143.7% to $0.38 during Wednesday's pre-market session. The company's market cap stands at $12.2 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock moved upwards by 62.87% to $1.14. The company's market cap stands at $109.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 46.15% to $2.09. The market value of their outstanding shares is at $4.1 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares rose 34.59% to $0.38. The company's market cap stands at $14.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock rose 25.49% to $3.2. The market value of their outstanding shares is at $61.0 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 19.34% to $4.01. The market value of their outstanding shares is at $32.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares decreased by 62.3% to $5.48 during Wednesday's pre-market session. The market value of their outstanding shares is at $147.7 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 18.58% to $0.44. The company's market cap stands at $6.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock decreased by 14.49% to $3.07. The company's market cap stands at $7.9 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares fell 14.46% to $2.13. The company's market cap stands at $52.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 12.7% to $0.31. The company's market cap stands at $4.1 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock declined by 11.51% to $4.0. The market value of their outstanding shares is at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Stride, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and issued FY25 revenue <a href="https://www.benzinga.com/quote/LRN">guidance above estimates</a>.
Stride reported quarterly earnings of 94 cents per share which beat the analyst consensus estimate of 20 cents per share. The company reported quarterly sales of $551.084 million which beat the analyst consensus estimate of $506.081 million.
Stride shares jumped 24.3% to $80.25 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) rose 99.4% to $0.3124 in pre-market trading after jumping around 7% on Tuesday.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) gained 75.7% to $1.23 in pre-market trading as the company announced positive regulatory updates for the Viaskin&#xAE; Peanut Patch in the United States and Europe.</li>
<li>Mustang Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares surged 60.6% to $0.4531 in pre-market trading after declining around 4% on Tuesday.</li>
<li>Farmmi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAMI#NASDAQ">FAMI</a>) rose 55.2% to $0.4890 in pre-market trading after gaining 4% on Tuesday.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) shares rose 39.6% to $0.0885 in pre-market trading after dipping around 18% on Tuesday.</li>
<li>ShiftPixy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>) shares jumped 30.3% to $10.67 in pre-market trading. ShiftPixy signed a LOI to acquire AI innovator TurboScale in a $150 million deal.</li>
<li>Phunware, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) climbed 23.4% to $14.37 in pre-market trading after jumping 38% on Tuesday.</li>
<li>22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) gained 19.3% to $0.1387 in pre-market trading after gaining over 10% on Tuesday.</li>
<li>Daqo New Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares rose 15.8% to $24.10 in pre-market trading. Daqo New Energy will release its unaudited financial results for the third quarter before the opening bell on Wednesday, Oct. 30.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Alto Neuroscience, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares dipped 61.4% to $5.59 in pre-market trading after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.</li>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares fell 20.9% to $2.84 in pre-market trading after jumping around 138% on Tuesday.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) fell 19.3% to $0.4351 in pre-market trading after jumping 162% on Tuesday.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) fell 18.8% to $0.2973 in today's pre-market trading after jumping around 50% on Tuesday.</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) fell 18.2% to $0.7233 in pre-market trading after dipping 37% on Tuesday.</li>
<li>Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares fell 17.2% to $9.92 in pre-market trading.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) declined 15.2% to $78.21 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares declined 14.3% to $0.3023 in pre-market trading after gaining over 48% on Tuesday.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBP#NASDAQ">XBP</a>) shares declined 11.9% to $1.18 in pre-market trading.</li>
<li>McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) shares fell 7.2% to $292.20 following CDC reports of an E. coli outbreak linked to quarter pounders.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41479244/dow-edges-lower-as-investors-watch-earnings-reports-with-caution-fear-index-remains-in-greed-zone">Dow Edges Lower As Investors Watch Earnings Reports With Caution: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CHSN

DBGI

ENPH

FAMI

PHUN

PIXY

XXII

ZPTA

Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket

DBV Announces Positive Regulatory Updates for the Viaskin&#xAE; Peanut Patch in the United States and Europe
<ul>
<li>DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old&nbsp;</li>
<li>BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025</li>
<li>VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025&nbsp;&nbsp;</li>
<li>European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7 year-old indication in Europe</li>
<li>Company to host investor conference call at 5:00pm ET today &nbsp;</li>
</ul>
DBV Technologies (TRQX:<a href="https://www.benzinga.com/stock/DBVp#TRQX">DBVp</a>), a clinical-stage biopharmaceutical company, today announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the U.S. Food and Drug Administration (FDA) on a pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old and has also received scientific advice from the EMA on a 1 – 7 year-old indication in Europe. DBV intends to formalize the Accelerated Approval guidance provided by the FDA via submission of a meeting request.

Biotech

Global

DBV Announces Regulatory Updates For The Viaskin Peanut Patch In The U.S. And Europe; BLA Submission Under Accelerated Approval Is Subject To Completion Of A 6-Month Supplemental Safety Study In Toddlers To Be Initiated In Q2 2025; VITESSE Phase 3 Study Evaluating The Viaskin Peanut Patch In Children Ages 4 – 7 Years-old Exceeded Enrollment Goals

JMP Securities analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Outperform on DBV Technologies, Maintains $5 Price Target

DBV Technologies Completes Screening For VITESSE Phase 3 Trial Evaluating Viaskin Peanut Patch In Children Ages 4-7; Topline Results Expected By Q4 2025

HC Wainwright &amp; Co. analyst Andrew Fein reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Buy and maintains $5 price target.

HC Wainwright & Co. Reiterates Buy on DBV Technologies, Maintains $5 Price Target

JMP Securities analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and raises the price target from $4 to $5.

JMP Securities Maintains Market Outperform on DBV Technologies, Raises Price Target to $5

The Company intends to seek additional capital as it continues research and development efforts and prepares for the launch of Viaskin Peanut, if approved. The Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets due to any future pandemics, epidemics or global health crises and conflict in Ukraine or other global political or military crises. A severe or prolonged economic downturn could result in a variety of risks to the Company, including reduced ability to raise additional capital when needed or on acceptable terms, if at all.
If the Company is not successful in its financing objectives, the Company could have to scale back its operations, notably by delaying or reducing the scope of its research and development efforts or obtain financing through arrangements with collaborators or others that may require the Company to relinquish rights to its product candidates that the Company might otherwise seek to develop or commercialize independently.
This interim condensed financial information does not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company was unable to continue as a going concern.

DBV Technologies Faces Uncertainties In Securing Necessary Financing Under Favorable Terms Due To Potential Global Financial Disruptions, With Risks Exacerbated By Economic Downturns, Potentially Forcing Operational Scale-Backs Or Unwanted Collaborative Financial Arrangements, Without Adjustments Made In This Financial Statement For Going Concern Uncertainties

DBV Technologies shares are trading lower after the company reported mixed Q2 financial results. The company said there is substantial doubt regarding its ability to continue as a going concern.

DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 30.77 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $1.16 million which missed the analyst consensus estimate of $1.68 million by 30.89 percent. This is a 49.52 percent decrease over sales of $2.30 million the same period last year.

Earnings

DBV Technologies Q2 EPS $(0.34) Beats $(0.45) Estimate, Sales $1.16M Miss $1.68M Estimate

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares moved upwards by 124.3% to $0.98 during Thursday's pre-market session. The company's market cap stands at $4.9 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock increased by 116.82% to $2.32. The company's market cap stands at $5.4 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares increased by 36.65% to $0.44. The market value of their outstanding shares is at $4.3 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares moved upwards by 28.26% to $0.37. The company's market cap stands at $4.4 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares rose 27.08% to $1.15. The market value of their outstanding shares is at $17.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock increased by 24.99% to $2.0. The market value of their outstanding shares is at $47.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares decreased by 18.3% to $0.49 during Thursday's pre-market session. The company's market cap stands at $12.1 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock fell 15.93% to $0.39. The market value of their outstanding shares is at $30.2 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares fell 14.98% to $0.12. The company's market cap stands at $1.2 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) stock fell 13.28% to $0.98. The market value of their outstanding shares is at $42.5 million. </li>
<li>Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) shares fell 9.98% to $112.19. The company's market cap stands at $5.9 billion. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares decreased by 8.61% to $0.53. The market value of their outstanding shares is at $101.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

CERO

FRES

ISPC

MASI

NDRA

ONMD

RNLX

SXTP

12 Health Care Stocks Moving In Thursday's Pre-Market Session

DBV Technologies, a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (&quot;ADSs&quot;) to its ordinary shares (the &quot;ADS Ratio&quot;), nominal value &euro;0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the &quot;ADS Ratio Change&quot;) to be effective on or about June 3rd, 2024. The Company now anticipates that the ADS Ratio Change will be effective on or about June 7th, 2024 (the &quot;Effective Date&quot;).

&nbsp;

Stock Split

DBV Technologies Announces Plan To Implement ADS Ratio Change From 1 ADS To 1/2 Of A Ordinary Share To 1 ADS To 1 Ordinary Share, Anticipates That The ADS Ratio Change Will Be Effective On Or About June 7th, 2024

DBV Technologies Announces Plan to Implement ADS Ratio Change
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on or about June 3rd, 2024 (the "Effective Date").

DBV Technologies Announces Plan To Implement ADS Ratio Change From The Current ADS Ratio Of 1 ADS To 1/2 Of One 1 Ordinary Share To A New ADS Ratio Of One 1 ADS To 1 Ordinary Share

<h3>Gainers</h3>
<ul>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 19.67% to $0.15. The market value of their outstanding shares is at $18.7 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock increased by 16.7% to $0.51. The market value of their outstanding shares is at $2.7 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares moved upwards by 15.99% to $0.31. The company's market cap stands at $14.8 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares moved upwards by 15.5% to $0.12. The market value of their outstanding shares is at $4.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock increased by 13.36% to $0.65. The company's market cap stands at $125.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares declined by 13.6% to $0.92 during Thursday's pre-market session. The company's market cap stands at $46.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) shares decreased by 12.27% to $3.04. The company's market cap stands at $4.1 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) stock declined by 10.9% to $4.66. The market value of their outstanding shares is at $235.3 million. </li>
<li>Pieris Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) stock decreased by 10.12% to $10.22. The company's market cap stands at $12.6 million. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) stock decreased by 9.29% to $0.38. The market value of their outstanding shares is at $13.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares declined by 8.55% to $2.14. The company's market cap stands at $2.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DYNT

EYEN

GLUE

LSDI

NEXI

OTRK

PIRS

SINT

SSKN

WORX

HC Wainwright &amp; Co. analyst Andrew Fein maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Buy and lowers the price target from $10 to $5.

HC Wainwright & Co. Maintains Buy on DBV Technologies, Lowers Price Target to $5

Analyst Jonathan Wolleben from JMP Securities reiterated a Buy rating on DBV Technologies SA – American (DBVT – Research Report) and keeping the pr...

Buy Rating Affirmed for DBV Technologies on Strong VITESSE Trial Progress and FDA Collaboration

In a report released on September 24, Justine Telliez from Kepler Capital maintained a Buy rating on DBV Technologies (0QAJ – Research Report), wit...

Kepler Capital  Sticks to Their Buy Rating for DBV Technologies (0QAJ)

Warning: DBVT is at high risk of performing badly

The company states: "DBV Technologies (DBVT) announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DB...

DBV Technologies announces positive regulatory updates for Viaskin peanut patch

16:48 EDT DBV Technologies (DBVT) jumps 80% to $1.26 after Viaskin regulatory update Published first on TheFly – the ultimate source for real-time,...

DBV Technologies jumps 80% to $1.26 after Viaskin regulatory update

DBV Tech spikes after regulatory update on lead asset

Press Releases

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

Comments

DBV Technologies

DBV Technologies (DBVT) Opciones

DBV Technologies (NASDAQ:DBVT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL